HomeAI · summaries
Storia in 14 fonti
Tumore al pancreas: nuovo trattamento in compresse raddoppia la sopravvivenza
La FDA ha approvato daraxonrasib per il cancro al pancreas metastatico: 13,2 mesi di sopravvivenza contro 6,7 della chemio.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
forbes.com
FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque
Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
- ·
medpagetoday.com
'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval
RAS inhibitor daraxonrasib doubled survival outcomes in second-line trial
